MGD management needed for ocular prosthesis wearers

Article

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD).

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD), states the latest paper in the British Journal of Ophthalmology.

A team headed by Dr Jin Sook Yoon, Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Korea, assigned a survey to 30 consecutive patients with unilateral ocular prosthesis to identify MGD-related ocular symptoms.

All patients underwent slit lamp examination, meibography imaging and Fourier-domain (FD) optical coherence tomography (OCT) scanning on both eyelids. The main outcome measures were assessed using intra-individual comparison between the eyelids of a prosthetic eye and paired normal eyelids.

Eyelids with ocular prosthesis presented with significantly higher scores for ocular symptoms, lid margin abnormality, meibomian gland expression and meibography compared to normal eyelids.

Tear parameters in the eyelids with prosthetic eyes were significantly lower than normal eyelids. Overall ocular symptom score was significantly positively correlated with meibography score and negatively associated with tear parameters. Clinical evaluation and management recommendations for MGD would highly benefit patients with prosthetic eyes, especially those demonstrating ocular discomfort.

Please click here to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.